Seeds Investor LLC Sells 842 Shares of Elevance Health, Inc. (NYSE:ELV)

Seeds Investor LLC lowered its position in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) by 42.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,130 shares of the company's stock after selling 842 shares during the period. Seeds Investor LLC's holdings in Elevance Health were worth $417,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of ELV. Norges Bank acquired a new position in shares of Elevance Health during the fourth quarter valued at $1,135,014,000. Wellington Management Group LLP raised its position in shares of Elevance Health by 42.5% during the 4th quarter. Wellington Management Group LLP now owns 6,355,532 shares of the company's stock worth $2,344,556,000 after buying an additional 1,893,947 shares in the last quarter. First Eagle Investment Management LLC lifted its stake in shares of Elevance Health by 47.6% in the 4th quarter. First Eagle Investment Management LLC now owns 3,225,339 shares of the company's stock worth $1,189,828,000 after acquiring an additional 1,039,612 shares during the period. Orion Portfolio Solutions LLC boosted its holdings in shares of Elevance Health by 6,817.8% in the fourth quarter. Orion Portfolio Solutions LLC now owns 908,795 shares of the company's stock valued at $335,254,000 after acquiring an additional 895,658 shares in the last quarter. Finally, Artisan Partners Limited Partnership boosted its holdings in shares of Elevance Health by 17.9% in the fourth quarter. Artisan Partners Limited Partnership now owns 2,875,850 shares of the company's stock valued at $1,060,901,000 after acquiring an additional 437,103 shares in the last quarter. Institutional investors and hedge funds own 89.24% of the company's stock.

Elevance Health Stock Down 2.4 %

ELV stock traded down $10.60 during mid-day trading on Friday, hitting $424.44. The stock had a trading volume of 3,569,359 shares, compared to its average volume of 1,450,101. Elevance Health, Inc. has a 1-year low of $362.21 and a 1-year high of $567.26. The company has a fifty day moving average of $416.11 and a 200 day moving average of $411.67. The company has a current ratio of 1.45, a quick ratio of 1.50 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $96.09 billion, a price-to-earnings ratio of 16.57, a PEG ratio of 1.18 and a beta of 0.77.

Elevance Health (NYSE:ELV - Get Free Report) last released its quarterly earnings data on Thursday, January 23rd. The company reported $3.84 EPS for the quarter, topping analysts' consensus estimates of $3.80 by $0.04. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%. On average, equities analysts expect that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 25th. Stockholders of record on Monday, March 10th were paid a dividend of $1.71 per share. This represents a $6.84 annualized dividend and a dividend yield of 1.61%. The ex-dividend date was Monday, March 10th. This is an increase from Elevance Health's previous quarterly dividend of $1.63. Elevance Health's dividend payout ratio is 26.71%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ELV. Robert W. Baird restated a "neutral" rating and issued a $529.00 target price (down from $625.00) on shares of Elevance Health in a research report on Tuesday. Wells Fargo & Company lowered their target price on Elevance Health from $483.00 to $478.00 and set an "overweight" rating on the stock in a report on Tuesday, January 28th. Sanford C. Bernstein reissued an "outperform" rating on shares of Elevance Health in a report on Friday, March 28th. Truist Financial increased their target price on shares of Elevance Health from $480.00 to $510.00 and gave the company a "buy" rating in a research note on Friday, April 11th. Finally, Barclays raised their price objective on Elevance Health from $501.00 to $512.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. Four investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $514.41.

Insider Activity

In other Elevance Health news, CAO Ronald W. Penczek sold 443 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $415.13, for a total transaction of $183,902.59. Following the transaction, the chief accounting officer now owns 1,847 shares in the company, valued at $766,745.11. This trade represents a 19.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of the business's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $396.30, for a total transaction of $1,388,635.20. Following the completion of the sale, the executive vice president now owns 10,116 shares of the company's stock, valued at $4,008,970.80. The trade was a 25.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.29% of the stock is currently owned by insiders.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.